Tango Therapeutics, Inc. (TNGX) Stock
TNGX has an Alpha Score of 38 out of 100 (weak), computed on Nov 1, 2026 from 2 of 4 sub-scores. 5 of the hedge funds AlphaScala tracks reported TNGX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $23.39M. Company insiders reported 0 open-market buys and 10 sales on SEC Form 4 in the 90 days to Nov 6, 2026.
What is TNGX's Alpha Score?
How it works →Alpha Score of 38 reflects weak overall profile with moderate momentum, moderate quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 1, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own TNGX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 748K | $23.39M | NEW |
| Millennium Management Israel Englander | 496K | $15.51M | +17% |
| Point72 Steve Cohen | 298K | $9.33M | -44% |
| Citadel Ken Griffin | 181K | $5.66M | +1% |
| Marshall Wace | 175K | $5.47M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Tango Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 2, 26 | Newcomb Jessica | Principal Accounting Officer | SELL | 5.6K | $124K |
| Nov 2, 26 | Newcomb Jessica | Principal Accounting Officer | SELL | 1.5K | $34K |
| Nov 2, 26 | Crystal Adam | President, R&D | SELL | 3.9K | $87K |
| Nov 2, 26 | Crystal Adam | President, R&D | SELL | 1.1K | $25K |
| Oct 1, 26 | Crystal Adam | President, R&D | SELL | 26.4K | $646K |
| Oct 1, 26 | Crystal Adam | President, R&D | SELL | 600 | $15K |
| Sep 22, 26 | Newcomb Jessica | Principal Accounting Officer | SELL | 700 | $16K |
| Sep 22, 26 | Newcomb Jessica | Principal Accounting Officer | SELL | 5.1K | $122K |
| Sep 22, 26 | Newcomb Jessica | Principal Accounting Officer | SELL | 2.4K | $60K |
| Sep 1, 26 | Crystal Adam | President, R&D | SELL | 27.0K | $604K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are TNGX's key statistics?
Key statistics as of Nov 1, 2026
How does TNGX's valuation compare with the Healthcare sector?
| Metric | TNGX | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -151.15% | 3.66% | 170 |
| Return on equity | -25.74% | 3.71% | 194 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 9, 2026). P/E excludes loss-making companies.
TNGX price chart
Powered by TradingViewWhat does Tango Therapeutics, Inc. do?
Tango Therapeutics is a clinical-stage precision oncology company focused on discovering and developing novel cancer medicines for patients with defined genetic vulnerabilities and unmet medical needs. Founded in 2017 and headquartered in Boston, Massachusetts, the company leverages the principle of synthetic lethality to create genetically targeted therapies that exploit specific tumor characteristics. Tango Therapeutics' pipeline includes several investigational candidates: TNG462, a methylthioadenosine-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor in Phase 1/2 clinical trials for pancreatic and lung cancer patients; TNG456, a brain-penetrant PRMT5 inhibitor for glioblastoma treatment; and TNG260, a co-repressor inhibitor designed to reverse immune evasion in lung cancer. The company's approach targets defined patient populations with specific genetic mutations, including MTAP-deleted and RAS-mutant cancers. Tango Therapeutics pursues strategic collaborations with major pharmaceutical partners to advance its precision cancer medicine pipeline and expand the reach of genetically targeted therapies in oncology.